Holen Sie sich die Stockscreener-App
8.525
7.09%
0.555
Schlusskurs vom Vortag:
$7.97
Offen:
$8.3
24-Stunden-Volumen:
575.13K
Relative Volume:
1.44
Marktkapitalisierung:
$2.57B
Einnahmen:
$391.87M
Nettoeinkommen (Verlust:
$-441.45M
KGV:
-4.6081
EPS:
-1.85
Netto-Cashflow:
$-301.21M
1W Leistung:
-1.22%
1M Leistung:
+6.29%
6M Leistung:
+0.06%
1J Leistung:
-31.72%
1-Tages-Spanne:
$8.2445
$8.59
1-Wochen-Bereich:
$7.97
$8.96
52-Wochen-Spanne:
$7.35
$13.70
Alvotech Stock (ALVO) Company Profile
Vergleichen Sie ALVO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALVO
Alvotech
|
8.525 | 2.57B | 391.87M | -441.45M | -301.21M | -1.85 |
|
ZTS
Zoetis Inc
|
143.48 | 63.05B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.79 | 43.33B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.18 | 40.43B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.14 | 22.97B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
433.24 | 19.90B | 3.08B | 1.24B | 1.07B | 25.61 |
Alvotech Stock (ALVO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-23 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-14 | Eingeleitet | UBS | Buy |
| 2024-01-29 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-09-21 | Eingeleitet | Barclays | Equal Weight |
| 2022-09-07 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-09-06 | Herabstufung | Citigroup | Buy → Sell |
| 2022-07-26 | Eingeleitet | Citigroup | Buy |
Alle ansehen
Alvotech Aktie (ALVO) Neueste Nachrichten
Alvotech (NASDAQ:ALVO) Shares Gap UpHere's Why - MarketBeat
Detecting price anomalies in Alvotech Equity Warrant with AIEarnings Summary Report & Long-Term Capital Growth Ideas - newser.com
Why Alvotech’s Stock is Climbing Higher - TipRanks
ALVO Rating Upgraded to Overweight by Morgan Stanley | ALVO Stoc - GuruFocus
Morgan Stanley Upgrades Alvotech to Overweight From Equalweight, Price Target is $14 - MarketScreener
What does recent volatility data suggest for Alvotech2025 Institutional Moves & Weekly High Return Stock Forecasts - newser.com
Will Alvotech Equity Warrant stock go up soon2025 Pullback Review & Stock Portfolio Risk Management - newser.com
Is Alvotech stock positioned for digital transformationWeekly Profit Report & Fast Exit and Entry Strategy Plans - newser.com
Morgan Stanley upgrades Alvotech stock rating to Overweight on global growth - Investing.com
Can Alvotech Equity Warrant stock outperform in 2025 bull marketInsider Selling & Reliable Breakout Stock Forecasts - newser.com
Volatility clustering patterns for Alvotech Equity WarrantPrice Action & Free Technical Confirmation Trade Alerts - newser.com
Best data tools to analyze Alvotech stock2025 Risk Factors & Reliable Breakout Forecasts - newser.com
Chart based analysis of Alvotech trendsQuarterly Profit Report & Pattern Based Trade Signal System - newser.com
Is Alvotech trending in predictive chart modelsOptions Play & High Accuracy Swing Trade Signals - newser.com
Does Alvotech stock trade at a discount to peersWeekly Trend Recap & Community Trade Idea Sharing Platform - newser.com
Predicting Alvotech Equity Warrant trend using moving averages2025 Big Picture & Technical Buy Zone Confirmation - newser.com
Is Alvotech Equity Warrant stock supported by innovation pipelineEarnings Overview Report & AI Forecasted Entry and Exit Points - newser.com
Backtesting results for Alvotech Equity Warrant trading strategiesJuly 2025 Technicals & Fast Momentum Stock Entry Tips - newser.com
Analyzing Alvotech with risk reward ratio chartsJuly 2025 Trends & Momentum Based Trading Ideas - newser.com
Comparing Alvotech Equity Warrant in custom built stock radarsJuly 2025 Big Picture & Low Risk High Win Rate Stock Picks - newser.com
Volume spikes in Alvotech stock – what they mean2025 Big Picture & High Conviction Buy Zone Picks - newser.com
Alvotech Equity Warrant stock trendline breakdownQuarterly Trade Review & High Win Rate Trade Tips - newser.com
Alvotech’s AVT23 Biosimilar Gains EMA Acceptance - MSN
Statistical indicators supporting Alvotech Equity Warrant’s strengthPortfolio Update Summary & Real-Time Chart Pattern Alerts - newser.com
How to read the order book for AlvotechJuly 2025 Price Swings & Capital Protection Trading Alerts - newser.com
Using Ichimoku Cloud for Alvotech technicalsCPI Data & Stock Market Timing Techniques - newser.com
Will Alvotech (Z45) stock beat revenue estimatesJuly 2025 Highlights & Growth Oriented Trade Recommendations - newser.com
Will Alvotech Equity Warrant stock benefit from green energy trendsJuly 2025 Catalysts & Safe Investment Capital Preservation Plans - newser.com
News impact scoring models applied to Alvotech Equity Warrant2025 Major Catalysts & Entry Point Confirmation Signals - newser.com
Alvotech Equity Warrant stock trend outlook and recovery path2025 Technical Patterns & Real-Time Buy Signal Notifications - newser.com
Alvotech's (ALVO) Sell (E+) Rating Reiterated at Weiss Ratings - MarketBeat
Here's How Alvotech is Expanding its Portfolio Beyond Immunology - MSN
Alvotech And Advanz Celebrate EU Omalizumab Filing - insights.citeline.com
European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency - Sahm
European Marketing Application for AVT23, a Proposed - GlobeNewswire
My Top 5 Biotech Stocks Big Pharma Could Buy Next - Seeking Alpha
ALVO: EMA Begins Review of AVT23; Advanz Holds Commercial Rights - Stock Titan
Will Alvotech Equity Warrant stock recover after recent dropBuy Signal & Momentum Based Trading Ideas - newser.com
EMA accepts application for Alvotech's AVT23 - Biostock
Advanz Pharma and Alvotech Announce EMA Acceptance of Marketing Application for Biosimilar AVT23 to Xolair® - Quiver Quantitative
Alvotech: EMA Accepts MAA for AVT23, biosimilar to Xolair | ALVO Stock News - Stock Titan
Real time breakdown of Alvotech Equity Warrant stock performanceQuarterly Profit Report & Daily Profit Focused Screening - newser.com
EMA Recommendations for AVT03 and Gobivaz Could Be a Game Changer for Alvotech (ALVO) - simplywall.st
Finanzdaten der Alvotech-Aktie (ALVO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.02%
2.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):